EMA, Drug Giants Join Push To Reform Vaccine Monitoring

Law360, New York (November 26, 2013, 5:37 PM EST) -- The European Medicines Agency and Pfizer Ltd., Novartis Pharma AG and other drugmakers joined an initiative Tuesday designed to create a continentwide framework for assessing the benefits and drawbacks of vaccines after they have been approved for use.

The project — known as the Accelerated Development of Vaccine Benefit-Risk Collaboration in Europe, or Advance — aims to streamline the compilation of data to determine the benefit-risk profile of already-marketed vaccines and to more quickly communicate those benefits and risks to the public.

In addition to the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.